NO20020130L - Anvendelse av FVIIa eller en vevsfaktorantagonist til regulering av genekspresjon og cellemigrasjon eller kjemotaksis - Google Patents

Anvendelse av FVIIa eller en vevsfaktorantagonist til regulering av genekspresjon og cellemigrasjon eller kjemotaksis

Info

Publication number
NO20020130L
NO20020130L NO20020130A NO20020130A NO20020130L NO 20020130 L NO20020130 L NO 20020130L NO 20020130 A NO20020130 A NO 20020130A NO 20020130 A NO20020130 A NO 20020130A NO 20020130 L NO20020130 L NO 20020130L
Authority
NO
Norway
Prior art keywords
cell migration
fviia
chemotaxis
gene expression
tissue factor
Prior art date
Application number
NO20020130A
Other languages
English (en)
Norwegian (no)
Other versions
NO20020130D0 (no
Inventor
Mirella Ezban
Lars Christian Petersen
Agneta Siegbahn
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO20020130D0 publication Critical patent/NO20020130D0/no
Publication of NO20020130L publication Critical patent/NO20020130L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
NO20020130A 1999-07-14 2002-01-11 Anvendelse av FVIIa eller en vevsfaktorantagonist til regulering av genekspresjon og cellemigrasjon eller kjemotaksis NO20020130L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA199901023 1999-07-14
US14830099P 1999-08-11 1999-08-11
DKPA199901117 1999-08-12
PCT/DK2000/000401 WO2001005353A2 (en) 1999-07-14 2000-07-14 USE OF FVIIa OR A TISSUE FACTOR ANTAGONIST FOR REGULATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS

Publications (2)

Publication Number Publication Date
NO20020130D0 NO20020130D0 (no) 2002-01-11
NO20020130L true NO20020130L (no) 2002-03-13

Family

ID=27221063

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020130A NO20020130L (no) 1999-07-14 2002-01-11 Anvendelse av FVIIa eller en vevsfaktorantagonist til regulering av genekspresjon og cellemigrasjon eller kjemotaksis

Country Status (19)

Country Link
US (3) US20020193302A1 (de)
EP (1) EP1200116B1 (de)
JP (1) JP2003525028A (de)
KR (1) KR100821644B1 (de)
CN (1) CN100411684C (de)
AT (1) ATE411041T1 (de)
AU (1) AU5807500A (de)
BR (1) BR0012408A (de)
CA (1) CA2378249A1 (de)
CZ (1) CZ200240A3 (de)
DE (1) DE60040539D1 (de)
ES (1) ES2316372T3 (de)
HU (1) HUP0302052A3 (de)
IL (1) IL147294A0 (de)
MX (1) MXPA02000468A (de)
NO (1) NO20020130L (de)
PL (1) PL353035A1 (de)
RU (1) RU2268744C2 (de)
WO (1) WO2001005353A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001271365A1 (en) * 2000-06-21 2002-01-02 Wyeth Cyr61 as a target for treatment and diagnosis of breast cancer
DE10238429A1 (de) 2002-03-19 2003-10-30 Aventis Behring Gmbh Intellect Marburg I Mutante der Faktor VII aktivierenden Protease (FSAP) als Risikofaktor für Atherosklerose
US6858587B2 (en) 2001-11-02 2005-02-22 Novo Nordisk Pharmaceuticals, Inc. Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
WO2003037361A2 (en) * 2001-11-02 2003-05-08 Novo Nordisk Health Care Ag Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
WO2003065871A2 (en) * 2002-02-04 2003-08-14 Millennium Pharmaceuticals Inc. Methods and compositions for treating hematological disorders
WO2005040187A2 (en) * 2003-08-06 2005-05-06 Hans Prydz The use of sirna silencing in the prevention of metastasis
MXPA06011952A (es) * 2004-04-16 2007-01-16 Scripps Research Inst Metodo para modulacion de vascularizacion.
ZA200804082B (en) * 2005-11-07 2010-02-24 Scripps Research Inst Compositions and methods for controlling tissue factor signaling specificity
WO2008103812A1 (en) * 2007-02-21 2008-08-28 Yale University Compositions and methods for diagnosing and treating endometriosis
CN102971415B (zh) * 2011-07-01 2016-06-01 株式会社资生堂 血小板源性生长因子-bb产生增强剂、以及包含该增强剂的间充质系干细胞产生促进剂、干细胞稳定剂和真皮再生剂
CN109381478A (zh) * 2018-10-31 2019-02-26 青岛大学附属医院 一种miRNA在制备抑制新生血管生成和抑制VEGF-A因子表达的试剂中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2123338C1 (ru) * 1990-06-15 1998-12-20 Сайтел Корпорейшн Фармацевтическая композиция на основе медиатора межклеточной адгезии (варианты), способ ингибирования межклеточной адгезии, способ лечения воспалительного заболевания, способ анализа тестируемого соединения на способность ингибировать клеточную адгезию, способ получения соединения
CA2121028A1 (en) * 1991-10-11 1993-04-15 Ulla K. E. Hedner Hemostatic composition for local hemostasis
DE19538715A1 (de) * 1995-10-18 1997-04-30 Behringwerke Ag Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
CN1263852C (zh) 1996-03-15 2006-07-12 穆尼恩公司 胞外基质信号分子
WO1998058661A1 (en) 1997-06-23 1998-12-30 Novo Nordisk A/S Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function
US20030040481A1 (en) * 1997-07-18 2003-02-27 Lars Kongsbak Methods for modifying cell motility using a factor VIIa antagonist
AU8101698A (en) * 1997-07-18 1999-02-10 Novo Nordisk A/S Use of fviia or fviiai for the treatment of adverse conditions related to the fviia mediated intracellular signalling pathway
AT408613B (de) * 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
IL157842A0 (en) 2001-03-22 2004-03-28 Novo Nordisk Healthcare Ag Coagulation factor vii derivatives
IL158615A0 (en) 2001-05-02 2004-05-12 Novo Nordisk As Modified factor vii in treatment of acute lung injury or acute respiratory distress syndrome
KR20040015821A (ko) 2001-07-20 2004-02-19 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ⅶ 폴리펩티드와 인자 ⅹⅰ폴리펩티드를 포함하는약학적 조성물
CN1596125A (zh) 2001-11-09 2005-03-16 诺和诺德医疗保健公司 包括因子ⅶ多肽和因子ⅴ多肽的药物组合物
EP1446148A1 (de) 2001-11-09 2004-08-18 Novo Nordisk A/S Pharmazeutische zusammensetzung mit einem faktor-vii-polypeptid und epsilon-aminocapronsäure
EP1446155A1 (de) 2001-11-09 2004-08-18 Novo Nordisk A/S Pharmazeutische zusammensetzung mit faktor-vii-polypeptiden und aprotinin-polypeptiden
WO2003039581A1 (en) 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and tranexamic acid

Also Published As

Publication number Publication date
CN1460024A (zh) 2003-12-03
KR20020025194A (ko) 2002-04-03
HUP0302052A3 (en) 2005-12-28
US20090036378A1 (en) 2009-02-05
CN100411684C (zh) 2008-08-20
US7829529B2 (en) 2010-11-09
EP1200116B1 (de) 2008-10-15
CA2378249A1 (en) 2001-01-25
IL147294A0 (en) 2002-08-14
JP2003525028A (ja) 2003-08-26
US20020193302A1 (en) 2002-12-19
AU5807500A (en) 2001-02-05
WO2001005353A2 (en) 2001-01-25
HUP0302052A2 (hu) 2003-09-29
US20050239708A1 (en) 2005-10-27
NO20020130D0 (no) 2002-01-11
KR100821644B1 (ko) 2008-04-11
PL353035A1 (en) 2003-10-06
CZ200240A3 (cs) 2003-04-16
DE60040539D1 (de) 2008-11-27
ES2316372T3 (es) 2009-04-16
BR0012408A (pt) 2002-03-12
MXPA02000468A (es) 2008-10-06
ATE411041T1 (de) 2008-10-15
EP1200116A2 (de) 2002-05-02
WO2001005353A3 (en) 2001-07-19
RU2268744C2 (ru) 2006-01-27

Similar Documents

Publication Publication Date Title
DE50310980D1 (de) VERWENDUNG VON I kappa B-KINASE INHIBITOREN IN DER SCHMERZTHERAPIE
NO20020130D0 (no) Anvendelse av FVIIa eller en vevsfaktorantagonist til regulering av genekspresjon og cellemigrering eller kjemotaksis
NO961888D0 (no) Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer av metallproteinaser
EP1581056A4 (de) Therapeutische retrovirus-vektoren für diegentherapie
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
ATE368731T1 (de) Menschliche cd45+ und/oder fibroblasten+ mesenchymale stammzellen
AU5338301A (en) Methods and compositions for modulating alpha adrenergic receptor activity
NO20052928L (no) Nye kjemiske forbindelser
ATE324105T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung von entzündungserkrankungen von kopf und nacken
MX2009004051A (es) Uso de antagonistas de il-1 para tratar gota y pseudo gota.
DK1218494T3 (da) Præparater og fremgangsmåder til inhibering af C2-cellecyklusstandsning og sensibilisering af celler til DNA-beskadigende midler
ATE275919T1 (de) Verwendung von metall-proteinase-inhibitoren, um das wachstum der haare oder körperhaare zu induzieren und/oder zu stimulieren und/oder den haarausfall zu verlangsamen
DE69738887D1 (de) Tumor necrosis factor rezeptor abspaltendes enzym, dessen zubereitungen und verwendungen
DK1171144T3 (da) Anvendelse af tetrahydrocurcuminoider til regulering af fysiologiske og patologiske forhold i huden og slimhinderne
ATE380558T1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
ATE427773T1 (de) Verwendung von n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-a1,3,4- xadiazol-2-yluphenyl)pyridin-3- sulphonamid in der tumortherapie
ATE362923T1 (de) 4-(phenylpiperazinylmethyl)benzamidderivate und deren verwendung zur behandlung von schmerzen oder gastrointestinalen erkrankungen
BR0315344A (pt) Métodos para prever edema como um efeito colateral do tratamento com drogas
TR200200278T2 (tr) Kalsilitik bileşimler
ATE242641T1 (de) Behandlung von stressinduzierten hautkrankheiten unter verwendung von corticoliberin (crh)- antagonisten und inhibitoren der hautmastzell- degranulation
ATE491442T1 (de) 1-phenyl-2- dimethylaminomethylcyclohexanverbindungen zur therapie von depressiven symptomatiken, schmerz und inkontinenz
ATE206052T1 (de) Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
NO20010390L (no) Behandling av angstsykdommer
ATE376416T1 (de) Verwendung von ambroxol zur behandlung von chronischen schmerzen
NO20045343L (no) Ny kombinasjon for behandling av luftveisforstyrrelser